Biotech News
Related news
CORTCorcept2026-06-17 20:28 EST
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
CORTCorcept2026-05-29 20:33 EST
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
NBIXNeurocrine Biosciences2026-05-18 12:46 EST
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
NBIXNeurocrine Biosciences2026-07-23 20:05 EST
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
CRNXCrinetics Pharmaceuticals2026-06-02 20:05 EST
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
AMPHAmphastar Pharmaceuticals, Inc.2020-10-06 10:00 EST
Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection
CRNXCrinetics Pharmaceuticals2026-01-04 21:00 EST
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
AMPHAmphastar Pharmaceuticals, Inc.2021-05-03 10:00 EST
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
Corcept
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...
Recent company news
CORTCorcept2026-07-29 20:05 EST
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
CORTCorcept2026-07-22 20:05 EST
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-06-17 20:28 EST
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
CORTCorcept2026-06-06 20:45 EST
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
CORTCorcept2026-05-29 20:33 EST
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Stock data
- Close
- 122.25 USD
- Market cap
- 7.64B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States